COSCIENS Biopharma Inc T.AEZ

Biomaterials

[prophetoffactz]

Perplexity Ai:

"The average time from submission to publication for an article in the journal Biomaterials is around 131 days."

It has been 62 days since AEZS said it "recently" submitted the article:

"A comprehensive scientific article was recently submitted to the Biomaterials scientific journal."

If by "recently" submitted it was 30 days prior the comprehensive journal article in Biomaterials could be published in as little at 39 days. 

In an October presentation Gilles believed a short 6 month toxicology study could be all that was needed to formally make a 'go'/'no go' trial decision. Could we soon see a comprehensive article published in a leading scientific journal, results from an anticipated toxicology study, and a formal 'go' decision for a human clinical trial? 

May 23, 2023 News Release:

"If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University."

McMaster's Dr. Martin Kolb worked on Avalyn Pharma's inhaled fibrosis drug with Dr. Ask(now with Novartis) and it raised ~C$80 million going into its Phase I trial. Avalyn more recently raised ~C$238 million. When Avalyn raised its money going into Phase I there was no COVID lung fibrosis. PGX-YBG/Fibrosis could also work outside the lungs and be an inhaled delivery platform for other drugs.

Dr. Kolb and Dr. Ask also recently published that the receptor PGX-YBG targets(dectin-1) is also upregulated in lung cancer:

"Conclusion: Dectin-1 is a macrophage receptor that is upregulated in both murine and human models of lung cancer and IPF serving as a potential therapeutic target to reprogram pathological macrophages."

Identifying the common denominator: Dectin-1 as a promising marker for macrophage modulation in lung cancer and fibrosis | European Respiratory Society (ersjournals.com)